Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs) | Zendy

Hélio S. Sader | Zendy; Susanne Paukner | Zendy; Zrinka IvezicSchoenfeld | Zendy; Dj Biedenbach | Zendy; F.-J. Schmitz | Zendy; R. N. Jones | Zendy

Open Access

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

Author(s) -

Hélio S. Sader,

Susanne Paukner,

Zrinka IvezicSchoenfeld,

Dj Biedenbach,

F.-J. Schmitz,

R. N. Jones

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks001

Subject(s) - antimicrobial , microbiology and biotechnology , antibiotics , respiratory tract infections , respiratory tract , biology , respiratory system , medicine

BC-3781 is an investigational semi-synthetic pleuromutilin antibiotic, which recently finished a clinical Phase 2 trial in acute bacterial skin and skin structure infections. BC-3781 binds to the 50S ribosomal subunit and cross-resistance with other antimicrobial classes is uncommon. We evaluated the activity of BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research